HEALTH● LOWSep 13 · Sep 13, 2026, 5:32 PM
Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy
Seeking Alpha Tech · north america
Scholar Rock's stock increased by 12% following FDA approval of its drug, isembyld, for spinal muscular atrophy. This article reports on a significant pharmaceutical development and its immediate financial impact.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH1h agoNAFDAC records 213 raids, 474 new cases in eight monthsPremium TimesHEALTHBREAKING1h agoKenya reports second Ebola case, family member of first patientFrance 24 [en]HEALTH1h agoVanda puts anxiety drug program on hold after Phase III setbackSeeking Alpha TechHEALTH2h agoSuspected Fake Surgeon Arrested In Rivers State, Eight Facilities SealedChannels TV